HUTCHMED (China) Limited

HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company's mission is to globally transform patient treatment through scientific rigor and collaborative efforts. Headquartered in Hong Kong, its corporate office is located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central.

HUTCHMED operates primarily through two segments: Oncology/Immunology and Other Ventures. The Oncology/Immunology segment focuses on its in-house drug discovery and development pipeline. Key marketed oncology products include ELUNATE® (fruquintinib) for metastatic colorectal cancer, ORPATHYS® (savolitinib) for non-small cell lung cancer, and SULANDA® (surufatinib) for neuroendocrine tumors, predominantly in China. Fruquintinib has also received approvals and is marketed in the US, EU, and Japan. The Other Ventures segment encompasses commercial activities such as prescription drug distribution in China.

As of late 2025 and early 2026, Johnny Cheng serves as the Acting Chief Executive Officer and Chief Financial Officer. The company reported a consolidated profit of $457 million for the full year 2025, significantly boosted by a non-core asset disposal. Recent developments include the initiation of a Phase III trial for HMPL-760 in relapsed/refractory diffuse large B-cell lymphoma in China in March 2026 and the New Drug Application (NDA) acceptance with priority review for sovleplenib for warm antibody autoimmune hemolytic anemia in China in April 2026. In March 2026, HUTCHMED announced the worldwide withdrawal of the licensed oncology product TAZVERIK® due to safety findings, a move not expected to impact its financial guidance. The company continues to advance its Antibody-Targeted Therapy Conjugate (ATTC) platform.